Haisco Pharmaceutical: Subsidiary obtains new veterinary drug registration certificate for methylprednisolone tablets.

Haizheng Pharmaceutical announced that its holding subsidiary, Haizheng Dongbao Company, has received the approval and issuance of the New Veterinary Drug Registration Certificate for Methylprednisolone Tablets from the Ministry of Agriculture and Rural Affairs. This product has officially been approved as a Class V new veterinary drug. Methylprednisolone tablets are used for the treatment of inflammation and allergic diseases in dogs, and were jointly developed by Haizheng Dongbao Company and 7 other companies. The acquisition of the new veterinary drug registration certificate signifies that the product meets relevant regulations, which will help to promote the company's strategic layout in the veterinary drug sector and enhance market competitiveness. At present, the product has the conditions for production and marketing, but will not have a significant impact on the company's performance in the short term.